PHNOM PENH, Cambodia--(BUSINESS WIRE)--In the list of subsidiaries, the release previously issued March 18, 2016 should read: Guangzhou Lu Sheng Health Consultancy Co. Ltd. (instead of Guangzhou Lv Sheng Health Consultancy Co. Ltd.) and Diamond Cell Sdn. Bhd. (instead of Zhong Sheng (M) Biotechnology Cell Insurance Centre).
The corrected release reads:
ANNOUNCEMENT: RIHC SETS SAIL FOR GLOBAL BUSINESS
Rorine International Holding Corporation (Company Number: 9353333) has been listed (RIHC) on OTC markets in America and RIHC subsidiaries include:-
1World Global Corporation
1World Cambodia Holdings
RICH International Entertainment
RICH Internet Ltd. Co.
RICH International Entertainment
RICH International Investment Ltd.
Rorine (Shenzhen) Investment Ltd.
Guangzhou Lu Sheng Health Consultancy Co. Ltd.
Guangzhou Tong De Diabetes Specialist Hospital
Diamond Cell Sdn. Bhd.
We predict future global economic development trends, based on current trends, to create a super multinational.
At the same time, we have set up a team of experts consisting of the best brains in marketing, business management as well as international investment to manage ASEAN enterprises out of our headquarters in Cambodia. The expert team, endowed with professionalism, pragmatism, keen business acumen and a passion for excellence, is entrusted with the mission of running various financial investments, business operations and highly specialised development projects overseas. The team represents one of the most responsible and societal-driven groups in ASEAN.
We lead our subsidiaries of diversified business concerns into different investment spectra to minimize risks. Presently our footprint covers real estate, financial investment, food & beverages, entertainment & gaming, video game, plantation as well as holiday resort. Our gold mine in Cambodia is running a second probe, and is expected to start its mining operations in June. The tin mining business in Indonesia kicked off in March 2016. After the mining activities, the site will be converted into a cultural tourist resort, complete with a cultural centre, an educational centre, a rehab centre, high-class standalone bungalows and the world’s largest peacock park, the entire project of which has been fully endorsed by the local government.
Having rooted firmly in China, Rorine International began to roll out its health industry brick-and-mortar projects all over China. With its advanced patented technology in biotechnology, it set foot initially in Guangzhou and Shenzhen, with the intention of spreading to various major cities in China. Meanwhile, we set up Tong De Diabetes Specialist Hospital in Guangzhou and linked its Type II diabetes treatment to 100 top 3 hospitals in mainland China. At the same time, we registered a patent throughout South-east Asian countries and established 100 diabetes treatment centre within the region.
Rorine International and Zhong Shen (Shenzhen) Health Investment Co. Ltd jointly created the largest cell insurance centre in South-east Asia and established Zhong Shen (M) Health Investment Co. Ltd in March 2016. The company plans, in 2 years, to store healthy cells from at least 500,000 families via an innovative business model!
Today, holding on to the company philosophy of ‘aggressiveness, pragmatism, rigour and unity’, we will continue to explore innovative technology and uplift our quality to propel the company into a world class label. We reaped a good harvest last year, gracefully transitioned from steady risk into growth phase. We foresee this new year, under the able leadership of our wise Board of Directors, will bring even better performance, with the Group forming strategic alliances with various enterprises in other industries.
Riding on its inherent strength and integrated resources, Rorine International is going to prop up its listed shares, elevating it from the initial value of USD0.60 to USD1.10.
Rorine International owes its striking achievements to various trades and people from all walks of life. With a new unique financial investment model, Rorine International will help a lot more caring enterprises in China to prosper via merger and acquisition, buy-over, strategic investment etc so as to knock together on the door of NASDAQ in America. We hope to get listed on the main board by 2018, at an IPO price of USD30 per share, so that the big Rorine International family can scale the summit of riches and realize our dreams hand-in-hand.
Thank You.
